The opening will help to grow the global workforce, deepen technology talent in the region, and support an international customer base
Illumina celebrated the opening of a global capability centre in Bengaluru, to grow its global workforce, deepen technology talent in the region, and support an international customer base. This planned move was originally announced in early September.
The Illumina office is located within Bengaluru’s Manyata Technology Park, a complex shared among global technology, healthcare, and biopharma companies. More than 80 Illumina employees currently work at the Manyata facility, with more than 200 employees anticipated at the site by the end of 2025. Illumina also operates a customer solutions centre in Bengaluru.
“We are thrilled to invest in India and expand our presence in Bengaluru,” said Illumina Chief Information Officer Carissa Rollins. “We look forward to tapping into India’s pool of high-calibre talent to bring forward diverse cultural perspectives that can drive organisational growth and innovation.”
“India is a country where Illumina can thrive and help Bengaluru become a centre for genomic discovery. It is known for its biotech infrastructure, skilled labour, life-sciences-based resources, and supportive public policies to advance genomic innovation,” said Kevin Pegels, Chief of Global Operations. "Expanding our global footprint allows us to operate and show up for our customers as one Illumina.”
Illumina’s workforce strategy is to build global teams with the skills and capabilities to enable innovation at scale and strengthen the company’s impact around the world. In addition to two sites in India, Illumina has a sequencing centre in Cambridge, England, and an innovation centre in Singapore, along with commercial offices in Asia, Oceania, Africa, the Middle East, Europe, and the Americas.
Illumina’s new global capability centre adds to an already growing footprint in the region. In 2023, Illumina opened a new office and state-of-the-art genomics lab—known as an Illumina Solutions Center—in Bengaluru. The facility provides training and education and features a fully equipped laboratory with the latest next-generation sequencing technologies.
Illumina’s other philanthropic support in India includes the company’s early COVIDSeq collaboration with the Council of Scientific and Industrial Research’s Institute of Genomics & Integrative Biology in New Delhi, its donation of $1 million in sequencing capabilities to Mumbai’s Kasturba Hospital for COVID surveillance, and its use of whole-genome sequencing to detect drug resistance in tuberculosis at P D Hinduja Hospital.
